Xenon to showcase long-term 36-month azetukalner data at aan 2025

Vancouver, british columbia and boston, april 04, 2025 (globe newswire) -- xenon pharmaceuticals inc. (nasdaq: xene), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming american academy of neurology annual meeting (aan 2025), taking place april 5-9, 2025 in san diego, ca. three posters will be presented, including long-term data from the ongoing x-tole open-label extension (ole) study of azetukalner in patients with focal onset seizures (fos). the company will also present an exploratory efficacy analysis of fos seizure subtypes from the x-tole study, as well as patient survey findings about the mental health and comorbidity burdens of fos.
AAN Ratings Summary
AAN Quant Ranking